SR9011 is a research drug that was developed by Professor Thomas Burris of Scripps as an agonist of Rev-ErbAα with a half-maximum inhibitory concentration (IC50) = 790 nM for Rev-Erbα and IC50 = 560 nM for Rev-ErbAβ.

[1] It has been used in the study of the regulation of the circadian rhythm and its links to immune system function, inflammation and cancer.

[2][3][4][5][6][7]

This pharmacology-related article is a stub.

You can help Wikipedia by expanding it.